Atrium Therapeutics (RNA) Stephanie Kenney Sells 2,375 Shares

What Happened Stephanie Kenney, Chief Corporate Affairs Officer of Atrium Therapeutics (RNA), had 2,375 shares withheld by the company to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs). The withholding was recorded at $8.95 per share, for a total value of $21,256. This is a tax-withholding disposition (not an open-market sale).

Key Details

• Transaction date: 2026-09-18; Form 4 filed: 2026-09-22 (filed within the required reporting window).
• Price per share: $8.95; Shares withheld/disposed: 2,375; Total value: $21,256.
• Footnote: F1 — shares were withheld by the issuer to satisfy tax withholding on RSU vesting.
• Shares owned after the transaction: not disclosed in this filing.
• Transaction code: F (tax withholding), not a purchase (P) or voluntary sale (S).

Context This transaction reflects routine employer tax withholding when RSUs vest (a cashless or share-withholding method to cover taxes). Such withholding transactions are common and do not necessarily indicate a change in the insider’s view of the company.